Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002236918 | SCV002510472 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 358 of the AARS protein (p.Gly358Val). This variant is present in population databases (rs370368784, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with AARS-related conditions. ClinVar contains an entry for this variant (Variation ID: 1682256). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV002292692 | SCV002585579 | uncertain significance | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | AARS1: PM2, PP3 |
Ambry Genetics | RCV004045106 | SCV004916631 | uncertain significance | Inborn genetic diseases | 2023-12-13 | criteria provided, single submitter | clinical testing | The c.1073G>T (p.G358V) alteration is located in exon 9 (coding exon 8) of the AARS gene. This alteration results from a G to T substitution at nucleotide position 1073, causing the glycine (G) at amino acid position 358 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |